Developments in the study of CD40/ CD40L gene and its polymorphism in atherosclerosis.
10.3969/j.issn.1672-7347.2012.04.017
- Author:
Tian WU
1
,
2
;
Ren GUO
;
Bikui ZHANG
Author Information
1. Department of Pharmacy, Third Xiangya Hospital
2. College of Pharmacy, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Atherosclerosis;
genetics;
physiopathology;
CD40 Antigens;
genetics;
CD40 Ligand;
genetics;
Humans;
Immunity;
physiology;
Inflammation;
physiopathology;
NF-kappa B;
metabolism;
Polymorphism, Genetic;
Thrombophilia;
physiopathology
- From:
Journal of Central South University(Medical Sciences)
2012;37(4):413-418
- CountryChina
- Language:Chinese
-
Abstract:
CD40/CD40L is a pair of complementary transmembrane glycoproteins, expressed on immune cells, endothelial cells, smooth muscle cells, platelets and other cells involved in regulation of immunity, inflammation, coagulation and other pathophysiologic states. A large number of researches have demonstrated that, when atherosclerosis occurs, CD40L ligates CD40; subsequently CD40 is activated and stimulates downstream signaling pathways, including nuclear factor-kappaB, with consequent up-regulation of proinflammatory and proatherogenic genes. Thus it plays an important role in the occurrence, development and plaque-rupture of atherosclerosis. CD40/CD40L is a bridge between immunity, inflammation, and a hypercoagulable state, and may be an important target for prevention and treatment of cardiovascular disease.
